Search

Your search keyword '"Surdo, L."' showing total 16 results
Start Over Author "Surdo, L."
16 results on '"Surdo, L."'

1. Physiological adaptations affecting drug pharmacokinetics in space: what do we really know? A critical review of the literature

Author

Dello Russo, Cinzia, Bandiera, T., Monici, M., Surdo, L., Yip, V. L. M., Wotring, V., Morbidelli, L., Dello Russo C. (ORCID:0000-0002-2538-3832), Dello Russo, Cinzia, Bandiera, T., Monici, M., Surdo, L., Yip, V. L. M., Wotring, V., Morbidelli, L., and Dello Russo C. (ORCID:0000-0002-2538-3832)

Abstract

As human spaceflight progresses with extended mission durations, the demand for effective and safe drugs will necessarily increase. To date, the accepted medications used during missions (for space motion sickness, sleep disturbances, allergies, pain, and sinus congestion) are administered under the assumption that they act as safely and efficaciously as on Earth. However, physiological changes have been documented in human subjects in spaceflight involving fluid shifts, muscle and bone loss, immune system dysregulation, and adjustments in the gastrointestinal tract and metabolism. These alterations may change the pharmacokinetics (PK) and pharmacodynamics of commonly used medications. Frustratingly, the information gained from bed rest studies and from in-flight observations is incomplete and also demonstrates a high variability in drug PK. Therefore, the objectives of this review are to report (i) the impact of the space environmental stressors on human physiology in relation to PK; (ii) the state-of-the-art on experimental data in space and/or in ground-based models; (iii) the validation of ground-based models for PK studies; and (iv) the identification of research gaps.

Published
2022

2. The Plastic Scintillator Detector of the HERD space mission

Author

Kyratzis, D., Alemanno, F., Altomare, C., Barbato, F. C. T., Bernardini, P., Cattaneo, P. W., Mitri, De, Palma, De, Venere, Di, Santo, Di, Fusco, M., Gargano, P., Loparco, F., Loporchio, F., Marsella, S., Mazziotta, G., Pantaleo, M. N., Parenti, F. R., Pillera, A., Rappoldi, R., Raselli, A., Rossella, G., Serini, M., Silveri, D., Surdo, L., Wu, A., Adriani, L., Aloisio, O., Ambrosi, G., An, G., Antonelli, Q., Azzarello, M., Bai, P., Bai, L., Bao, Y. L., Barbanera, T. W., Berti, M., Bertucci, B., Bi, B., Bigongiari, X. J., Bongi, G., Bonvicini, M., Bordas, V., Bosch-Ramon, P., Bottai, V., Brogi, S., Cadoux, P., Campana, F., Cao, D., Cao, W. W., Casaus, Z., Catanzani, J., Chang, E., Chang, J., Chen, Y. H., Chen, G. M., Cianetti, F., Comerma, F., Cortis, A., Cui, D., Cui, X. H., Dai, X. Z., Dai, C., D'Alessandro, Z. G., Gaetano, De, Felice, Di, Giovanni, Di, Dong, A., Dong, J. N., Donvito, Y. W., Duranti, G., D'Urso, M., Evoli, D., Fang, C., Fariña, K., Favre, L., Feng, Y., Feng, C. Q., Feng, H., Feng, H. B., Finetti, Z. K., Formato, N., Frieden, V., Gao, J. M., Gascon-Fora, J. R., Gasparrini, D., Giglietto, D., Giovacchini, N., Gomez, F., Gong, S., Gou, K., Guida, Q. B., Guo, R., Guo, D. Y., Guo, J. H., Y. Q., He, H. H., Hu, H. B., Hu, J. Y., Hu, Hu, P., Huang, Y. M., Huang, G. S., Huang, J., Huang, W. H., Huang, X. T., Huang, Y. B., Ionica, Y. F., Jouvin, M., Kotenko, L., Marra, La, Li, D., M. J., Li, Q. Y., Li, Li, R., S. L., Li, Li, T., Li, X., Li, Z., Liang, Z. H., Liang, E. W., Liao, M. J., Licciulli, C. L., Lin, F., Liu, S. J., Liu, D., Liu, H. B., Liu, H., Liu, J. B., Liu, S. B., Liu, X., Liu, X. W., Y. Q., Lu, Lyu, X., Lyu, J. G., Maestro, L. W., Mancini, E., Manera, E., Marin, R., Marrocchesi, J., Martinez, P. S., Martinez, G., Marzullo, M., Mauricio, D., Mocchiutti, J., Morettini, G., Mori, G., Mussolin, L., Oliva, L., Orlandi, A., Osteria, D., Pacini, G., Panico, L., Papa, B., Papini, S., Paredes, P., Pauluzzi, J. M., Pearce, M., Peng, M., Perfetto, W. X., Perrina, F., Perrotta, C., Pizzolotto, G., Qiao, C., Qin, R., Quadrani, J. J., Quan, L., Ren, Z., Renno, X. X., Ribo, F., Rico, M., Ryde, J., Sanmukh, F., Scotti, A., Shi, V., Shi, D. L., Starodubtsev, Q. Q., Su, O., D. T., Su, Sukhonos, M., Suma, D., Sun, A., Sun, X. L., Tang, Z. T., Tiberio, Z. C., Tykhonov, A., Vagelli, A., Vannuccini, V., Velasco, E., Walter, M., Wang, R., Wang, A. Q., Wang, B., Wang, J. C., Wang, J. M., Wang, J. J., Wang, L., Wang, M., Wang, R. J., Wang, S., Wang, X. Y., Wang, X. L., Wei, Z. G., Wei, D. M., J. J., Wu, B. B., Wu, Wu, J., L. B., Wu, Wu, X., Xin, X. F., Y. L., Xu, Xu, M., Yan, Z. Z., Yang, H. R., Yin, Y., P. F., Yu, Yuan, Y. W., Zampa, Q., Zampa, G., Zha, N., Zhang, M., Zhang, C., Zhang, F. Z., Zhang, L., Zhang, L. F., Zhang, S. N., Zhang, Y., Zhao, Y. L., Zheng, Z. G., Zhou, J. K., Zhu, Y. L., Zhu, F. R., and K. J.

Subjects
Energy, Gamma-ray astronomy, Charged particles, Gamma rays, High energy gamma rays, Measurements of, Space-borne instruments, Space stations, Mass composition, Space missions, Cosmology, Cosmic ray energy spectrum, Plastic scintillator detector, Precise measurements, Scintillation counters, Cosmic rays
Published
2022

4. The Future of Personalized Medicine in Space: From Observations to Countermeasures

Author

Pavez Lorie, E., Baatout, S., Chouker, A., Buchheim, J. -I., Baselet, B., Dello Russo, Cinzia, Wotring, V., Monici, M., Morbidelli, L., Gagliardi, D., Stingl, J. C., Surdo, L., Yip, V. L. M., Dello Russo C. (ORCID:0000-0002-2538-3832), Pavez Lorie, E., Baatout, S., Chouker, A., Buchheim, J. -I., Baselet, B., Dello Russo, Cinzia, Wotring, V., Monici, M., Morbidelli, L., Gagliardi, D., Stingl, J. C., Surdo, L., Yip, V. L. M., and Dello Russo C. (ORCID:0000-0002-2538-3832)

Abstract

The aim of personalized medicine is to detach from a “one-size fits all approach” and improve patient health by individualization to achieve the best outcomes in disease prevention, diagnosis and treatment. Technological advances in sequencing, improved knowledge of omics, integration with bioinformatics and new in vitro testing formats, have enabled personalized medicine to become a reality. Individual variation in response to environmental factors can affect susceptibility to disease and response to treatments. Space travel exposes humans to environmental stressors that lead to physiological adaptations, from altered cell behavior to abnormal tissue responses, including immune system impairment. In the context of human space flight research, human health studies have shown a significant inter-individual variability in response to space analogue conditions. A substantial degree of variability has been noticed in response to medications (from both an efficacy and toxicity perspective) as well as in susceptibility to damage from radiation exposure and in physiological changes such as loss of bone mineral density and muscle mass in response to deconditioning. At present, personalized medicine for astronauts is limited. With the advent of longer duration missions beyond low Earth orbit, it is imperative that space agencies adopt a personalized strategy for each astronaut, starting from pre-emptive personalized pre-clinical approaches through to individualized countermeasures to minimize harmful physiological changes and find targeted treatment for disease. Advances in space medicine can also be translated to terrestrial applications, and vice versa. This review places the astronaut at the center of personalized medicine, will appraise existing evidence and future preclinical tools as well as clinical, ethical and legal considerations for future space travel.

Published
2021

8. Volatile Extraction and Detection from Frozen Lunar Regolith Simulants in Preparation for the LUVMI Rover

Author

Pitcher, C., Sheridan, S., Barber, S. J., Urbina, D., Gancet, J., Kullack, K., Ceglia, E., Madakashira, H., Salinia, J., Govindaraj, S., Surdo, L., Aked, R., Biswas, J., Reiss, P., Richter, L., Dobrea, D., Reganaz, M., Murray, Neil, Rushton, J., Evagora, A., Pitcher, C., Sheridan, S., Barber, S. J., Urbina, D., Gancet, J., Kullack, K., Ceglia, E., Madakashira, H., Salinia, J., Govindaraj, S., Surdo, L., Aked, R., Biswas, J., Reiss, P., Richter, L., Dobrea, D., Reganaz, M., Murray, Neil, Rushton, J., and Evagora, A.

9. Volatile Extraction and Detection from Frozen Lunar Regolith Simulants in Preparation for the LUVMI Rover

Author

Pitcher, C., Sheridan, S., Barber, S. J., Urbina, D., Gancet, J., Kullack, K., Ceglia, E., Madakashira, H., Salinia, J., Govindaraj, S., Surdo, L., Aked, R., Biswas, J., Reiss, P., Richter, L., Dobrea, D., Reganaz, M., Murray, Neil, Rushton, J., Evagora, A., Pitcher, C., Sheridan, S., Barber, S. J., Urbina, D., Gancet, J., Kullack, K., Ceglia, E., Madakashira, H., Salinia, J., Govindaraj, S., Surdo, L., Aked, R., Biswas, J., Reiss, P., Richter, L., Dobrea, D., Reganaz, M., Murray, Neil, Rushton, J., and Evagora, A.

11. The effectiveness of progressive muscle relaxation and interactive guided imagery as a pain-reducing intervention in advanced cancer patients: A multicentre randomised controlled non-pharmacological trial

Author

Giuseppe Casale, Laura Surdo, Giulia De Paolis, Alessia Naccarato, Andrea D'Alete, Caterina Magnani, Chiara Mastroianni, Filomena Cibelli, De Paolis, G, Naccarato, A, Cibelli, F, D'Alete, A, Mastroianni, C, Surdo, L, Casale, G, and Magnani, C

Subjects
medicine.medical_specialty, Imagery, Psychotherapy, Autogenic training, medicine.medical_treatment, Psychological intervention, law.invention, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, Rating scale, law, Neoplasms, Medicine, Humans, Pain Management, 030212 general & internal medicine, Autogenic Training, Guided imagery, Progressive muscle relaxation, business.industry, Distress, Complementary and alternative medicine, Physical therapy, business, Cancer pain, 030217 neurology & neurosurgery
Abstract

Interactive guided imagery (IGI) and progressive muscle relaxation (PMR) are complementary therapies with a recognised positive effect on cancer pain relief. This multicentre randomised controlled trial was designed to assess the adjuvant effect of PMR-IGI in alleviating pain in a sample of hospice patients with terminal cancer.A total of 104 patients were randomised to two groups. Group A patients (n = 53) were administered the Revised Edmonton Symptom Assessment Scale (ESAS-r) and the numerical rating scale (NRS) for pain immediately prior to (T1) and 2 h following an individual PMR-IGI session (T3). Group B patients (n = 51) received usual care and were assessed using the same tools. Acute pain episodes and rescue analgesics over the following 24 h were recorded.The Pain Intensity Difference (NRS at T3-NRS at T1) was 1.83 in group A and 0.55 in group B and was significant in both groups (p 0.0001). The mean Total Symptom Distress Score declined by 8.83 in group A and by 1.84 in group B.The average difference in the emotional symptoms ESAS-r subscore (anxiety and depression) was 2.93 in group A (p 0.0001) and 0.07 in group B (p 0.05).The results of this trial suggest that PMR-IGI may be considered as an effective adjuvant in alleviating pain-related distress in terminal cancer patients. Further studies should be performed to assess the effectiveness of repeated interventions.

Published
2018

12. 3D Bioprinting in Microgravity: Opportunities, Challenges, and Possible Applications in Space.

Author

Van Ombergen A, Chalupa-Gantner F, Chansoria P, Colosimo BM, Costantini M, Domingos M, Dufour A, De Maria C, Groll J, Jungst T, Levato R, Malda J, Margarita A, Marquette C, Ovsianikov A, Petiot E, Read S, Surdo L, Swieszkowski W, Vozzi G, Windisch J, Zenobi-Wong M, and Gelinsky M

Subjects
Humans, Printing, Three-Dimensional, Weightlessness, Space Flight, Bioprinting, Cosmic Radiation
Abstract

3D bioprinting has developed tremendously in the last couple of years and enables the fabrication of simple, as well as complex, tissue models. The international space agencies have recognized the unique opportunities of these technologies for manufacturing cell and tissue models for basic research in space, in particular for investigating the effects of microgravity and cosmic radiation on different types of human tissues. In addition, bioprinting is capable of producing clinically applicable tissue grafts, and its implementation in space therefore can support the autonomous medical treatment options for astronauts in future long term and far-distant space missions. The article discusses opportunities but also challenges of operating different types of bioprinters under space conditions, mainly in microgravity. While some process steps, most of which involving the handling of liquids, are challenging under microgravity, this environment can help overcome problems such as cell sedimentation in low viscous bioinks. Hopefully, this publication will motivate more researchers to engage in the topic, with publicly available bioprinting opportunities becoming available at the International Space Station (ISS) in the imminent future., (© 2023 The Authors. Advanced Healthcare Materials published by Wiley-VCH GmbH.)

Published
2023
Full Text
View/download PDF

13. Physiological adaptations affecting drug pharmacokinetics in space: what do we really know? A critical review of the literature.

Author

Dello Russo C, Bandiera T, Monici M, Surdo L, Yip VLM, Wotring V, and Morbidelli L

Subjects
Adaptation, Physiological, Bed Rest, Humans, Space Flight, Weightlessness
Abstract

As human spaceflight progresses with extended mission durations, the demand for effective and safe drugs will necessarily increase. To date, the accepted medications used during missions (for space motion sickness, sleep disturbances, allergies, pain, and sinus congestion) are administered under the assumption that they act as safely and efficaciously as on Earth. However, physiological changes have been documented in human subjects in spaceflight involving fluid shifts, muscle and bone loss, immune system dysregulation, and adjustments in the gastrointestinal tract and metabolism. These alterations may change the pharmacokinetics (PK) and pharmacodynamics of commonly used medications. Frustratingly, the information gained from bed rest studies and from in-flight observations is incomplete and also demonstrates a high variability in drug PK. Therefore, the objectives of this review are to report (i) the impact of the space environmental stressors on human physiology in relation to PK; (ii) the state-of-the-art on experimental data in space and/or in ground-based models; (iii) the validation of ground-based models for PK studies; and (iv) the identification of research gaps., (© 2022 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.)

Published
2022
Full Text
View/download PDF

14. The Future of Personalized Medicine in Space: From Observations to Countermeasures.

Author

Pavez Loriè E, Baatout S, Choukér A, Buchheim JI, Baselet B, Dello Russo C, Wotring V, Monici M, Morbidelli L, Gagliardi D, Stingl JC, Surdo L, and Yip VLM

Abstract

The aim of personalized medicine is to detach from a "one-size fits all approach" and improve patient health by individualization to achieve the best outcomes in disease prevention, diagnosis and treatment. Technological advances in sequencing, improved knowledge of omics, integration with bioinformatics and new in vitro testing formats, have enabled personalized medicine to become a reality. Individual variation in response to environmental factors can affect susceptibility to disease and response to treatments. Space travel exposes humans to environmental stressors that lead to physiological adaptations, from altered cell behavior to abnormal tissue responses, including immune system impairment. In the context of human space flight research, human health studies have shown a significant inter-individual variability in response to space analogue conditions. A substantial degree of variability has been noticed in response to medications (from both an efficacy and toxicity perspective) as well as in susceptibility to damage from radiation exposure and in physiological changes such as loss of bone mineral density and muscle mass in response to deconditioning. At present, personalized medicine for astronauts is limited. With the advent of longer duration missions beyond low Earth orbit, it is imperative that space agencies adopt a personalized strategy for each astronaut, starting from pre-emptive personalized pre-clinical approaches through to individualized countermeasures to minimize harmful physiological changes and find targeted treatment for disease. Advances in space medicine can also be translated to terrestrial applications, and vice versa. This review places the astronaut at the center of personalized medicine, will appraise existing evidence and future preclinical tools as well as clinical, ethical and legal considerations for future space travel., Competing Interests: The handling editor declared a past collaboration with one of the authors MM. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Pavez Loriè, Baatout, Choukér, Buchheim, Baselet, Dello Russo, Wotring, Monici, Morbidelli, Gagliardi, Stingl, Surdo and Yip.)

Published
2021
Full Text
View/download PDF

15. Supportive and palliative care indicators tool (SPICT™): content validity, feasibility and pre-test of the Italian version.

Author

Casale G, Magnani C, Fanelli R, Surdo L, Goletti M, Boyd K, D'Angelo D, and Mastroianni C

Subjects
Aged, Feasibility Studies, Female, Humans, Italy, Male, Middle Aged, Psychometrics instrumentation, Psychometrics methods, Reproducibility of Results, Translating, Needs Assessment standards, Palliative Care methods, Psychometrics standards
Abstract

Background: Difficulties in identifying patients at risk of clinical deterioration or death represent one of the main barriers to Palliative Care (PC) development in the community. Currently, no specific Italian tools aimed at identifying patients with PC needs are available. Of the different European tools available, the SPICT™ can be used easily in any kind of setting and does not include the Surprise Question. The purpose of the study was to translate, cross-culturally adapt and pre-test the Italian version of the SPICT™., Methods: The Beaton recommendations for the cross-cultural adaptation of instruments were followed. Content validity was assessed using the Lynn method. A sample of Italian General Practitioners (GPs) assessed the SPICT-IT™ for feasibility and tested it., Results: During the cross-cultural adaptation, some issues regarding semantic, experiential, idiomatic and conceptual equivalences were raised and resolved. The Scale-Content Validity Index/Ave was 0.86. Of the 907 GPs included in the sample, 71 (7.8%) agreed to test the SPICT-IT™ and to assess its feasibility. The participants provided care for 73,526 people in the community. Of these people, 1.7% (N = 1303) were identified as being in need of PC according to the SPICT-IT™. Sixty-six (93.0%) GPs stated they would use the SPICT-IT™ in their daily clinical practice., Conclusions: The SPICT-IT™ demonstrated acceptable content validity. The percentage of patients identified through the SPICT-IT™ was comparable to findings from literature. The next phase of this project will investigate the impact of a proactive training programme aimed at supporting GPs in identifying patients with PC needs and delivering appropriate Primary Palliative Care (PPC).

Published
2020
Full Text
View/download PDF

16. The effectiveness of progressive muscle relaxation and interactive guided imagery as a pain-reducing intervention in advanced cancer patients: A multicentre randomised controlled non-pharmacological trial.

Author

De Paolis G, Naccarato A, Cibelli F, D'Alete A, Mastroianni C, Surdo L, Casale G, and Magnani C

Subjects
Humans, Autogenic Training, Imagery, Psychotherapy, Neoplasms physiopathology, Neoplasms therapy, Pain Management
Abstract

Background and Purpose: Interactive guided imagery (IGI) and progressive muscle relaxation (PMR) are complementary therapies with a recognised positive effect on cancer pain relief. This multicentre randomised controlled trial was designed to assess the adjuvant effect of PMR-IGI in alleviating pain in a sample of hospice patients with terminal cancer., Materials and Methods: A total of 104 patients were randomised to two groups. Group A patients (n = 53) were administered the Revised Edmonton Symptom Assessment Scale (ESAS-r) and the numerical rating scale (NRS) for pain immediately prior to (T1) and 2 h following an individual PMR-IGI session (T3). Group B patients (n = 51) received usual care and were assessed using the same tools. Acute pain episodes and rescue analgesics over the following 24 h were recorded., Results: The Pain Intensity Difference (NRS at T3-NRS at T1) was 1.83 in group A and 0.55 in group B and was significant in both groups (p < 0.0001). The mean Total Symptom Distress Score declined by 8.83 in group A and by 1.84 in group B.The average difference in the emotional symptoms ESAS-r subscore (anxiety and depression) was 2.93 in group A (p < 0.0001) and 0.07 in group B (p > 0.05)., Conclusion: The results of this trial suggest that PMR-IGI may be considered as an effective adjuvant in alleviating pain-related distress in terminal cancer patients. Further studies should be performed to assess the effectiveness of repeated interventions., (Copyright © 2019 Elsevier Ltd. All rights reserved.)

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results